ELITE PHARMACEUTIC COM USD0.01 (ELTP)

0.14
0.01 7.84
OTC
Prev Close 0.15
Open 0.15
Day Low/High 0.14 / 0.15
52 Wk Low/High 0.11 / 0.40
Volume 1.04M
Exchange OTC
Shares Outstanding 917.90B
Market Cap 137.68M
Div & Yield N.A. (N.A)

Latest News

Elite Pharmaceuticals, Inc. To Host Conference Call To Discuss 3rd Quarter 2017 Financial Results On February 13, 2017

Elite Pharmaceuticals, Inc. To Host Conference Call To Discuss 3rd Quarter 2017 Financial Results On February 13, 2017

Financials for 3rd Quarter Ended December 31, 2016 will be released on February 9, 2017

Elite Reports On SequestOx™ FDA End-of-Review Meeting

Elite Reports On SequestOx™ FDA End-of-Review Meeting

Elite Will Proceed with Studies Required for an NDA Resubmission

Elite Pharmaceuticals, Inc. Reports Financial Results For The Second Quarter Of Fiscal Year 2017 And Provides Conference Call Information

Elite Pharmaceuticals, Inc. Reports Financial Results For The Second Quarter Of Fiscal Year 2017 And Provides Conference Call Information

Conference Call Scheduled for Thursday, November 10th at 1:30 PM EST

Elite Pharmaceuticals, Inc. To Host Conference Call To Discuss 2nd Quarter 2017 Financial Results On November 10, 2016

Elite Pharmaceuticals, Inc. To Host Conference Call To Discuss 2nd Quarter 2017 Financial Results On November 10, 2016

Financials for 2nd Quarter Ended September 30, 2016 will be released on November 9, 2016

Trending Tickers: CZR, APO, MCUR, KS, ELTP

Trending Tickers: CZR, APO, MCUR, KS, ELTP

Caesars shares sink after a judge ruled that it would not be shielded from $11 billion in bondholder lawsuits.

Elite Pharmaceuticals, Inc. Reports Financial Results For The First Quarter Of Fiscal Year 2017 And Provides Conference Call Information

Elite Pharmaceuticals, Inc. Reports Financial Results For The First Quarter Of Fiscal Year 2017 And Provides Conference Call Information

Conference Call Scheduled for Thursday, August 11th  at 11:00 AM EDT

Elite Pharmaceuticals Announces Changes To Their Board Of Directors

Elite Pharmaceuticals Announces Changes To Their Board Of Directors

Gene Pfeifer Joins Elite's Board

Elite Announces U.S. FDA Priority Review Designation For SequestOx™ NDA

Elite Announces U.S. FDA Priority Review Designation For SequestOx™ NDA

SequestOx™ NDA Submission Accepted for Review

Elite Pharmaceuticals, Inc. Reports Strong Growth For Third Quarter Of Fiscal Year 2016

Elite Pharmaceuticals, Inc. Reports Strong Growth For Third Quarter Of Fiscal Year 2016

Conference Call Scheduled for Wednesday, February 10th at 11:30 AM EST

Elite Pharmaceuticals, Inc. To Host Conference Call To Discuss 3rd Quarter 2016 Financial Results On February 10, 2016

Elite Pharmaceuticals, Inc. To Host Conference Call To Discuss 3rd Quarter 2016 Financial Results On February 10, 2016

Financials for 3rd Quarter Ended December 31, 2015 Will be Released on February 9, 2016

FDA Approves Waiver Of NDA Filing Fee For Elite Pharmaceuticals

FDA Approves Waiver Of NDA Filing Fee For Elite Pharmaceuticals

Elite to Submit New Drug Application for ELI-200

Elite Pharmaceuticals, Inc. Reports Strong Growth For Second Quarter Of Fiscal Year 2016

Elite Pharmaceuticals, Inc. Reports Strong Growth For Second Quarter Of Fiscal Year 2016

Webcast and Conference Call Scheduled for Tuesday, November 10th at 11:00 AM EST

Elite Pharmaceuticals, Inc. To Host Conference Call And Webcast To Discuss 2nd Quarter 2016 Financial Results On November 10, 2015

Elite Pharmaceuticals, Inc. To Host Conference Call And Webcast To Discuss 2nd Quarter 2016 Financial Results On November 10, 2015

Financials for 2nd Quarter Ended September 30, 2015 will be released on November 9, 2015

Elite Pharmaceuticals, Inc. Reports Record Revenues For First Quarter Of Fiscal Year 2016

Elite Pharmaceuticals, Inc. Reports Record Revenues For First Quarter Of Fiscal Year 2016

Webcast and Conference Call Scheduled for Tuesday, August 11th at 11:00 AM EDT